Description: Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton's Tyrosine Kinase (BTK), which has reached candidate nomination stage. The Company's oncology research activity also include Porcupine program, Colony Stimulating Factor-1 receptor (CSF-1) program, Indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitor and Pan-Raf inhibitor. The Company's anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX003, is a class of antibiotic acting through the type II bacterial topoisomerases. It is also evaluating BTK inhibitor for immunological disorders.
Home Page: www.redxpharma.com
REDX Technical Analysis
Alderley Park
Macclesfield,
SK10 4TG
United Kingdom
Phone:
44 16 2546 9900
Officers
| Name | Title |
|---|---|
| Ms. Lisa Mary Whewell Anson | CEO & Exec. Director |
| Dr. James Mead | Chief Operating Officer |
| Mr. Peter J. Collum | Chief Financial Officer |
| Dr. Richard Armer | Chief Scientific Officer |
| Dr. Karl Hard Ph.D. | Head of Investor Relations |
| Ms. Claire Solk | Gen. Counsel & Company Sec. |
| Ms. Caitlin Pearson | Head of Communications |
| Dr. Jane Robertson | Chief Medical Officer |
| Dr. Cliff Jones | Sr. VP of Chemistry, DMPK & Intellectual Property |
| Dr. Caroline Phillips | Sr. VP of Biology |
Exchange: LSE
Country: UK : United Kingdom
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 37.9732 |
| Price-to-Sales TTM: | 12.2191 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |